Related Experiment Video

Updated: Apr 28, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Predicting hepatic steatosis and liver fat content in obese children based on biochemical parameters and

H-X Zhang1, X-Q Xu, J-F Fu

  • 1Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.

Pediatric Obesity
|June 7, 2014
PubMed

Insights

This study developed a liver fat score and equation using simple measurements to help doctors identify fatty liver disease in obese children. These tools accurately predict hepatic steatosis and liver fat content.

Area of Science:

  • Pediatric Endocrinology
  • Hepatology
  • Medical Imaging

Background:

  • Predicting hepatic steatosis and liver fat content (LFC) in obese children using general practice data is challenging.
  • Limited understanding of reliable clinical and laboratory predictors for pediatric fatty liver disease.

Purpose of the Study:

  • To develop predictive models for hepatic steatosis and LFC in obese children.
  • Utilize biochemical parameters and anthropometry for model development.

Main Methods:

  • Proton magnetic resonance spectroscopy used to quantify hepatic steatosis and LFC in 171 obese children.
  • Analysis included routine clinical, laboratory parameters, and anthropometric measurements.
  • Multivariate regression models created to develop a liver fat score and equation.

Main Results:

  • A predictive model for hepatic steatosis, using waist circumference and alanine aminotransferase, achieved an AUC of 0.959.
  • The model demonstrated high sensitivity (93%) and specificity (90%) for detecting hepatic steatosis.
  • A liver fat equation was derived from the same parameters to calculate individual LFC.

Conclusions:

  • A liver fat score and equation using routinely available variables can aid pediatricians in assessing hepatic steatosis and LFC.
  • External validation is recommended prior to clinical implementation of these tools.
Abstract

Keywords:
Biochemical parameters and anthropometryhepatic steatosisliver fat contentproton magnetic resonance spectroscopy

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

574

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
439
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.3K